September, 19 2018
Lille (France), 19 September 2018 - ALZPROTECT, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease, today announces that it has launched a study on the effect of food intake for its drug candidate AZP2006.
The dietary effect study is a randomized, single-dose crossover study to investigate the potential effects of food intake on the pharmacokinetics of AZP2006 administered orally to 14 healthy volunteers.
Previous Phase I clinical studies in 88 subjects had demonstrated that after oral administration, AZP2006 was well absorbed by the intestine and well tolerated by healthy volunteers. "This food effects study will explore the optimal timing of AZP2006 versus food intake. On the other hand, the results will make it possible to follow up on the next phase 2 clinical study in patients, planned for...
March, 26 2018
Lille (France), March 26th 2018 – ALZPROTECT, Biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease, announced today the hiring of its director of pharmaceutical development.
Noëlle Callizot is an international expert in the pharmaceutical and biotech industry. For 20 years, she has enabled the pharmaceutical development of neuroactive molecules up to advanced clinical stage. As director of neuropharmacology in the UK for 6 years, she has led various programs in neurodegenerative diseases (Alzheimer's, Parkinson's, etc.). Noëlle Callizot is co-founder of 4 biotech companies in fields as varied as contract research, functional neuro-rehabilitation, screening and neuro-active molecules. President of the AFMTELETHON Pharma Commission, Ms. Callizot also chairs several strategic programs for the AFM.
Noëlle Callizot will put into...